<DOC>
	<DOCNO>NCT00843635</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , tadalafil , may stimulate immune system different way stop tumor cell grow . PURPOSE : This randomized clinical trial study well tadalafil work treat patient undergo surgery cancer oral cavity oropharynx .</brief_summary>
	<brief_title>Tadalafil Treating Patients Undergoing Surgery Cancer Oral Cavity Oropharynx</brief_title>
	<detailed_description>OBJECTIVES : - To analyze phenotype function tumor-induced suppressive network associate squamous cell carcinoma ( SCC ) head neck patient SCC oral cavity oropharynx treat tadalafil follow definitive surgical resection . - To analyze immune response treatment tadalafil determine whether tadalafil treatment modulate patient . - To compare two dos tadalafil determine whether measurable difference immune response patient . - To analyze treatment-related side effect tadalafil two dos test patient . OUTLINE : Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral tadalafil daily day 1-20 absence unacceptable toxicity . - Arm II : Patients receive oral tadalafil ( high dose arm I ) daily day 1-20 absence unacceptable toxicity . - Arm III : Patients receive oral placebo daily day 1-20 absence unacceptable toxicity . All patient undergo schedule definitive surgical resection day 23 . Patients undergo blood sample collection baseline , day 20 , 6 week surgical resection correlative laboratory study . Patients also undergo tumor tissue sample collection baseline time surgical resection . Samples analyze immunological marker Fluorescence-activated cell sort ( FACS ) Immunohistochemistry ( IHC ) . After completion study treatment , patient follow periodically least 3 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients surgically resectable oral cavity SCC , subsites , T1 T4 , N0 N3 Patients surgically resectable oropharyngeal SCC , subsites , T1 T2 , N0 N1 Patients surgically resectable T4 oropharyngeal SCC , subsites , N0 N3 Patients must 18 year old old EXCLUSION CRITERIA : Patients previous surgical resection , radiation , chemotherapy exclude rule possible effect local tissue change secondary previous treatment Patients surgically unresectable disease primary site regional lymph node Patients T1 T2 SCC oropharynx , N2 N3 Patients T3 SCC oropharynx , N0 N3 Any patient nonsurgical therapy recommend treatment choice multidisciplinary treatment evaluation Patients alter mental status capacitate medical decision making Patients severe unstable cardiac cerebrovascular disease exclude myocardial infarction within last 90 day unstable angina angina occur sexual intercourse New York Heart Association Class 2 great heart failure last 6 month uncontrolled arrhythmias hypotension ( &lt; 90/50 mm Hg ) , uncontrolled hypertension ( &gt; 170/100 mm Hg ) stroke within last 6 month Left ventricle outflow obstruction . Pregnant nursing mother enrol give unknown effect offspring Concurrent nitrate , alphablocker , cytochrome P450 inhibitor use Renal Insufficiency define creatinine clearance less 51 . Creatinine clearance determine follow CockcroftGault Equation : ( 140age ) * ( Wt kg ) * ( 0.85 female ) / ( 72 * Cr ) Patients hepatic insufficiency . Patients currently take Phosphodiesterase ( PDE ) inhibitor erectile dysfunction Patients immunocompromised , reason directly relate patient malignancy Patients significant alcohol drug abuse Patients unilateral blindness , hereditary retinal disorder , increase risk blindness Patients unilateral deafness , history hearing loss , hear aid dependence , clinically evident hearing loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I verrucous carcinoma oral cavity</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
</DOC>